The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.02

Today's change-0.03 -1.46%
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.02

Today's change-0.03 -1.46%
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc down (U.S.)$0.03

PDL BioPharma Inc closed lower Friday, dropping (U.S.)$0.03 or 1.46% to (U.S.)$2.02. Over the last five days, shares have lost 0.98% and sit 4.66% above their 52-week low. This security has underperformed the S&P 500 by 58.29% during the last year.

Key company metrics

  • Open(U.S.) $2.05
  • Previous close(U.S.) $2.05
  • High(U.S.) $2.09
  • Low(U.S.) $2.01
  • Bid / Ask(U.S.) $2.00 / (U.S.) $2.14
  • YTD % change-4.72%
  • Volume1,748,698
  • Average volume (10-day)1,869,519
  • Average volume (1-month)1,909,953
  • Average volume (3-month)2,041,040
  • 52-week range(U.S.) $1.93 to (U.S.) $3.84
  • Beta0.58
  • Trailing P/E5.21×
  • P/E 1 year forward11.22×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.39
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.07%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue665421103
Total other revenue--------
Total revenue665421103
Gross profit62------
Total cost of revenue4------
Total operating expense77211010
Selling / general / administrative1310710
Research & development22----
Depreciation / amortization66----
Interest expense (income), net operating--------
Unusual expense (income)5713--
Other operating expenses, total-62----
Operating income-10331193
Interest income (expense), net non-operating-5-5-4-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-1528789
Income after tax-1014456
Income tax, total-414333
Net income-1014456
Total adjustments to net income--------
Net income before extra. items-1014456
Minority interest00----
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1014456
Inc. avail. to common incl. extra. items-1014456
Diluted net income-1014456
Dilution adjustment--------
Diluted weighted average shares164164164164
Diluted EPS excluding extraordinary itemsvalue per share-0.060.080.030.34
Dividends per sharevalue per share--0.000.050.05
Diluted normalized EPSvalue per share0.160.090.040.34